FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1216-1226 September 25, 2003 Number 13 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Khosla, S. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Because parathyroid hormone increases both bone formation and bone resorption, it is possible that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone mineral density.

Methods We randomly assigned 83 men who were 46 to 85 years of age and had low bone density to receive alendronate (10 mg daily; 28 men), parathyroid hormone (40 µg subcutaneously daily; 27 men), or both (28 men). Alendronate therapy was given for 30 months; parathyroid hormone therapy was begun at month 6. The bone mineral density of the lumbar spine, proximal femur, radial shaft, and total body was measured every six months with the use of dual-energy x-ray absorptiometry. Trabecular bone mineral density of the lumbar spine was measured at base line and month 30 by means of quantitative computed tomography. Serum alkaline phosphatase levels were measured every six months. The primary end point was the rate of change in the bone mineral density at the posteroanterior spine.

Results The bone mineral density at the lumbar spine increased significantly more in men treated with parathyroid hormone alone than in those in the other groups (P<0.001 for both comparisons). The bone mineral density at the femoral neck increased significantly more in the parathyroid hormone group than in the alendronate group (P<0.001) or the combination-therapy group (P=0.01). The bone mineral density of the lumbar spine increased significantly more in the combination-therapy group than in the alendronate group (P<0.001). At 12 months, changes in the serum alkaline phosphatase level were significantly greater in the parathyroid hormone group than in the alendronate group or the combination-therapy group (P<0.001 for both comparisons).

Conclusions Alendronate impairs the ability of parathyroid hormone to increase the bone mineral density at the lumbar spine and the femoral neck in men. This effect may be attributable to an attenuation of parathyroid hormone–induced stimulation of bone formation by alendronate.

Source Information

From the Endocrine Unit, Department of Medicine (J.S.F., A.H., J.L.H., J.J.W., R.M.N.), and the Biostatistics Center (H.L.), Massachusetts General Hospital, Boston.

This article was published at www.nejm.org on September 20, 2003.

Address reprint requests to Dr. Finkelstein at the Endocrine Unit, Bulfinch 327, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, or at jfinkelstein{at}partners.org.

Full Text of this Article

Related Letters:

Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Osteoporosis
Vegni F. E., Corradini C., Privitera G., Sugiyama T., Tanaka H., Kawai S., Miller P. D., Fuller K. E., Black D. M., Bilezikian J., Rosen C. J., the PaTH (Parathyroid Hormone and Alendronate) Study Investigators , Finkelstein J. S., Neer R. M.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:189-192, Jan 8, 2004. Correspondence

This article has been cited by other articles:

• Kawano, T., Troiano, N., Adams, D. J., Jun Wu, J., Sun, B.-h., Insogna, K. (2008). The Anabolic Response to Parathyroid Hormone Is Augmented in Rac2 Knockout Mice. Endocrinology 149: 4009-4015 [Abstract] [Full Text]  
• Nemeth, E. F. (2008). Anabolic Therapy for Osteoporosis: Calcilytics. IBMS BoneKEy 5: 196-208 [Abstract] [Full Text]  
• Khosla, S., Amin, S., Orwoll, E. (2008). Osteoporosis in Men. Endocr. Rev. 29: 441-464 [Abstract] [Full Text]  
• Ebeling, P. R. (2008). Osteoporosis in Men. NEJM 358: 1474-1482 [Full Text]  
• Stroup, J., Kane, M. P., Abu-Baker, A. M. (2008). Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 65: 532-539 [Abstract] [Full Text]  
• Raggatt, L. J., Qin, L., Tamasi, J., Jefcoat, S. C. Jr., Shimizu, E., Selvamurugan, N., Liew, F. Y., Bevelock, L., Feyen, J. H. M., Partridge, N. C. (2008). Interleukin-18 Is Regulated by Parathyroid Hormone and Is Required for Its Bone Anabolic Actions. J. Biol. Chem. 283: 6790-6798 [Abstract] [Full Text]  
• Boonen, S., Marin, F., Obermayer-Pietsch, B., Simoes, M. E., Barker, C., Glass, E. V., Hadji, P., Lyritis, G., Oertel, H., Nickelsen, T., McCloskey, E. V., for the EUROFORS Investigators, (2008). Effects of Previous Antiresorptive Therapy on the Bone Mineral Density Response to Two Years of Teriparatide Treatment in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab. 93: 852-860 [Abstract] [Full Text]  
• Lloyd, S. A.J., Travis, N. D., Lu, T., Bateman, T. A. (2008). Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse. J. Appl. Physiol. 104: 729-738 [Abstract] [Full Text]  
• Zaruba, M.-M., Huber, B. C., Brunner, S., Deindl, E., David, R., Fischer, R., Assmann, G., Herbach, N., Grundmann, S., Wanke, R., Mueller-Hoecker, J., Franz, W.-M. (2008). Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res 77: 722-731 [Abstract] [Full Text]  
• Schluter, K.-D., Schreckenberg, R., Wenzel, S. (2008). Stem cell mobilization versus stem cell homing: potential role for parathyroid hormone?. Cardiovasc Res 77: 612-613 [Full Text]  
• MacLaughlin, E. J., Raehl, C. L. (2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm 65: 343-357 [Full Text]  
• Garnero, P., Vergnaud, P., Hoyle, N. (2008). Evaluation of a Fully Automated Serum Assay for Total N-Terminal Propeptide of Type I Collagen in Postmenopausal Osteoporosis. Clin. Chem. 54: 188-196 [Abstract] [Full Text]  
• Li, X., Qin, L., Bergenstock, M., Bevelock, L. M., Novack, D. V., Partridge, N. C. (2007). Parathyroid Hormone Stimulates Osteoblastic Expression of MCP-1 to Recruit and Increase the Fusion of Pre/Osteoclasts. J. Biol. Chem. 282: 33098-33106 [Abstract] [Full Text]  
• Johnston, S., Andrews, S., Shen, V., Cosman, F., Lindsay, R., Dempster, D. W., Iida-Klein, A. (2007). The Effects of Combination of Alendronate and Human Parathyroid Hormone(1 34) on Bone Strength Are Synergistic in the Lumbar Vertebra and Additive in the Femur of C57BL/6J Mice. Endocrinology 148: 4466-4474 [Abstract] [Full Text]  
• Canalis, E., Giustina, A., Bilezikian, J. P. (2007). Mechanisms of Anabolic Therapies for Osteoporosis. NEJM 357: 905-916 [Full Text]  
• Samadfam, R., Xia, Q., Goltzman, D. (2007). Pretreatment with Anticatabolic Agents Blunts But Does Not Eliminate the Skeletal Anabolic Response to Parathyroid Hormone in Oophorectomized Mice. Endocrinology 148: 2778-2787 [Abstract] [Full Text]  
• Shoback, D. (2007). Update in Osteoporosis and Metabolic Bone Disorders. J. Clin. Endocrinol. Metab. 92: 747-753 [Abstract] [Full Text]  
• Antoniucci, D. M., Sellmeyer, D. E., Bilezikian, J. P., Palermo, L., Ensrud, K. E., Greenspan, S. L., Black, D. M. (2007). Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis. J. Clin. Endocrinol. Metab. 92: 942-947 [Abstract] [Full Text]  
• Wang, Y.-H., Liu, Y., Rowe, D. W. (2007). Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures. Am. J. Physiol. Endocrinol. Metab. 292: E594-E603 [Abstract] [Full Text]  
• Allison, S. J., Baldock, P., Sainsbury, A., Enriquez, R., Lee, N. J., Lin, E.-J. D., Klugman, M., During, M., Eisman, J. A., Li, M., Pan, L. C., Herzog, H., Gardiner, E. M. (2006). Conditional Deletion of Hypothalamic Y2 Receptors Reverts Gonadectomy-induced Bone Loss in Adult Mice. J. Biol. Chem. 281: 23436-23444 [Abstract] [Full Text]  
• Finkelstein, J. S., Leder, B. Z., Burnett, S.-A. M., Wyland, J. J., Lee, H., de la Paz, A. V., Gibson, K., Neer, R. M. (2006). Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men. J. Clin. Endocrinol. Metab. 91: 2882-2887 [Abstract] [Full Text]  
• Cranney, A., Papaioannou, A., Zytaruk, N., Hanley, D., Adachi, J., Goltzman, D., Murray, T., Hodsman, A., for the Clinical Guidelines Committee of Osteoporo, (2006). Parathyroid hormone for the treatment of osteoporosis: a systematic review.. CMAJ 175: 52-59 [Abstract] [Full Text]  
• Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., Udagawa, N., Takahashi, N., Tanaka, K., Oiso, Y., Seino, Y. (2006). Gastric Inhibitory Polypeptide as an Endogenous Factor Promoting New Bone Formation after Food Ingestion. Mol. Endocrinol. 20: 1644-1651 [Abstract] [Full Text]  
• Wright, V. J. (2006). Osteoporosis in Men. J Am Acad Orthop Surg 14: 347-353 [Abstract] [Full Text]  
• Yakar, S., Bouxsein, M. L, Canalis, E., Sun, H., Glatt, V., Gundberg, C., Cohen, P., Hwang, D., Boisclair, Y., LeRoith, D., Rosen, C. J (2006). The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone.. J Endocrinol 189: 289-299 [Abstract] [Full Text]  
• Woo, J.-T., Kawatani, M., Kato, M., Shinki, T., Yonezawa, T., Kanoh, N., Nakagawa, H., Takami, M., Lee, K. H., Stern, P. H., Nagai, K., Osada, H. (2006). Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc. Natl. Acad. Sci. USA 103: 4729-4734 [Abstract] [Full Text]  
• FURLOW, B. (2006). Osteoporosis in Men. radtech 77: 226-235 [Abstract] [Full Text]  
• Helvering, L. M., Liu, R., Kulkarni, N. H., Wei, T., Chen, P., Huang, S., Lawrence, F., Halladay, D. L., Miles, R. R., Ambrose, E. M., Sato, M., Ma, Y. L., Frolik, C. A., Dow, E. R., Bryant, H. U., Onyia, J. E. (2005). Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifene. Mol. Pharmacol. 68: 1225-1238 [Abstract] [Full Text]  
• Iida-Klein, A, Lu, S S., Kapadia, R, Burkhart, M, Moreno, A, Dempster, D W, Lindsay, R (2005). Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol 186: 549-557 [Abstract] [Full Text]  
• Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., Rosen, C. J., the PaTH Study Investigators, (2005). One Year of Alendronate after One Year of Parathyroid Hormone (1-84) for Osteoporosis. NEJM 353: 555-565 [Abstract] [Full Text]  
• Cosman, F., Nieves, J., Zion, M., Woelfert, L., Luckey, M., Lindsay, R. (2005). Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. NEJM 353: 566-575 [Abstract] [Full Text]  
• Rosen, C. J. (2005). Postmenopausal Osteoporosis. NEJM 353: 595-603 [Full Text]  
• McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., Eriksen, E. F. (2005). Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Arch Intern Med 165: 1762-1768 [Abstract] [Full Text]  
• Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., Orwoll, E., Yuen, C. K. (2005). Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. Endocr. Rev. 26: 688-703 [Abstract] [Full Text]  
• Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., Dunstan, C. R., Kostenuik, P. J. (2005). The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology 146: 3235-3243 [Abstract] [Full Text]  
• Komarova, S. V. (2005). Mathematical Model of Paracrine Interactions between Osteoclasts and Osteoblasts Predicts Anabolic Action of Parathyroid Hormone on Bone. Endocrinology 146: 3589-3595 [Abstract] [Full Text]  
• Yamaguchi, M., Ogata, N., Shinoda, Y., Akune, T., Kamekura, S., Terauchi, Y., Kadowaki, T., Hoshi, K., Chung, U.-I., Nakamura, K., Kawaguchi, H. (2005). Insulin Receptor Substrate-1 Is Required for Bone Anabolic Function of Parathyroid Hormone in Mice. Endocrinology 146: 2620-2628 [Abstract] [Full Text]  
• Teitelbaum, S. L. (2005). Osteoporosis and Integrins. J. Clin. Endocrinol. Metab. 90: 2466-2468 [Full Text]  
• (2005). Undertreatment of Osteoporosis in Men. Arch Intern Med 165: 241-241 [Full Text]  
• Schlechte, J. A. (2005). Update in Endocrinology. ANN INTERN MED 142: 126-131 [Full Text]  
• Rodeo, S. A., Maher, S. A., Hidaka, C. (2004). What's New in Orthopaedic Research. JBJS 86: 2085-2095 [Full Text]  
• Buxton, E. C., Yao, W., Lane, N. E. (2004). Changes in Serum Receptor Activator of Nuclear Factor-{kappa}B Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1-34). J. Clin. Endocrinol. Metab. 89: 3332-3336 [Abstract] [Full Text]  
• London, G. M., Marty, C., Marchais, S. J., Guerin, A. P., Metivier, F., de Vernejoul, M.-C. (2004). Arterial Calcifications and Bone Histomorphometry in End-Stage Renal Disease. J. Am. Soc. Nephrol. 15: 1943-1951 [Abstract] [Full Text]  
• (2004). Additional articles abstracted in ACP Journal Club. Evid. Based Med. 9: 67-67 [Full Text]  
• Cappuzzo, K. A, Delafuente, J. C (2004). Teriparatide for Severe Osteoporosis. The Annals of Pharmacotherapy 38: 294-302 [Abstract] [Full Text]  
• Vegni, F. E., Corradini, C., Privitera, G., Sugiyama, T., Tanaka, H., Kawai, S., Miller, P. D., Fuller, K. E., Black, D. M., Bilezikian, J., Rosen, C. J., the PaTH (Parathyroid Hormone and Alendronate) Stu, , Finkelstein, J. S., Neer, R. M. (2004). Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Osteoporosis. NEJM 350: 189-192 [Full Text]  
• Brown, S. A., Sharpless, J. L. (2004). Osteoporosis: An Under-appreciated Complication of Diabetes. Clin. Diabetes 22: 10-20 [Abstract] [Full Text]  
• Khosla, S. (2003). Parathyroid Hormone plus Alendronate -- A Combination That Does Not Add Up. NEJM 349: 1277-1279 [Full Text]